129 results on '"Dubnov-Raz, G"'
Search Results
2. Associations Between Maternal Depression, Antidepressant Use During Pregnancy, and Adverse Pregnancy Outcomes: An Individual Participant Data Meta-analysis.
- Author
-
Vlenterie, R., Gelder, M.M.H.J. van, Anderson, H.R., Andersson, L., Broekman, B.F.P., Dubnov-Raz, G., Marroun, H. El, Ferreira, E., Fransson, E., Heijden, F.M.M.A. van der, Holzman, C.B., Kim, J.J., Khashan, A.S., Kirkwood, B.R., Kuijpers, H.J.M.E., Lahti-Pulkkinen, M., Mason, D., Misra, D., Niemi, M., Nordeng, H.M.E., Peacock, J.L., Pickett, K.E., Prady, S.L., Premji, S.S., Räikkönen, K., Rubertsson, C., Sahingoz, M., Shaikh, K., Silver, R.K., Slaughter-Acey, J., Soremekun, S., Stein, D.J., Sundström-Poromaa, I., Sutter-Dallay, A.L., Tiemeier, H., Uguz, F., Varela, P., Vrijkotte, T.G., Winterfeld, U., Zar, H.J., Zervas, I.M., Prins, J.B., Pop-Purceleanu, M., Roeleveld, N., Vlenterie, R., Gelder, M.M.H.J. van, Anderson, H.R., Andersson, L., Broekman, B.F.P., Dubnov-Raz, G., Marroun, H. El, Ferreira, E., Fransson, E., Heijden, F.M.M.A. van der, Holzman, C.B., Kim, J.J., Khashan, A.S., Kirkwood, B.R., Kuijpers, H.J.M.E., Lahti-Pulkkinen, M., Mason, D., Misra, D., Niemi, M., Nordeng, H.M.E., Peacock, J.L., Pickett, K.E., Prady, S.L., Premji, S.S., Räikkönen, K., Rubertsson, C., Sahingoz, M., Shaikh, K., Silver, R.K., Slaughter-Acey, J., Soremekun, S., Stein, D.J., Sundström-Poromaa, I., Sutter-Dallay, A.L., Tiemeier, H., Uguz, F., Varela, P., Vrijkotte, T.G., Winterfeld, U., Zar, H.J., Zervas, I.M., Prins, J.B., Pop-Purceleanu, M., and Roeleveld, N.
- Abstract
Item does not contain fulltext, OBJECTIVE: To evaluate the associations of depressive symptoms and antidepressant use during pregnancy with the risks of preterm birth, low birth weight, small for gestational age (SGA), and low Apgar scores. DATA SOURCES: MEDLINE, EMBASE, ClinicalTrials.gov, and PsycINFO up to June 2016. METHODS OF STUDY SELECTION: Data were sought from studies examining associations of depression, depressive symptoms, or use of antidepressants during pregnancy with gestational age, birth weight, SGA, or Apgar scores. Authors shared the raw data of their studies for incorporation into this individual participant data meta-analysis. TABULATION, INTEGRATION, AND RESULTS: We performed one-stage random-effects meta-analyses to estimate odds ratios (ORs) with 95% CIs. The 215 eligible articles resulted in 402,375 women derived from 27 study databases. Increased risks were observed for preterm birth among women with a clinical diagnosis of depression during pregnancy irrespective of antidepressant use (OR 1.6, 95% CI 1.2-2.1) and among women with depression who did not use antidepressants (OR 2.2, 95% CI 1.7-3.0), as well as for low Apgar scores in the former (OR 1.5, 95% CI 1.3-1.7), but not the latter group. Selective serotonin reuptake inhibitor (SSRI) use was associated with preterm birth among women who used antidepressants with or without restriction to women with depressive symptoms or a diagnosis of depression (OR 1.6, 95% CI 1.0-2.5 and OR 1.9, 95% CI 1.2-2.8, respectively), as well as with low Apgar scores among women in the latter group (OR 1.7, 95% CI 1.1-2.8). CONCLUSION: Depressive symptoms or a clinical diagnosis of depression during pregnancy are associated with preterm birth and low Apgar scores, even without exposure to antidepressants. However, SSRIs may be independently associated with preterm birth and low Apgar scores. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42016035711.
- Published
- 2021
3. A Newly Developed Wearable Chest Strap for Measuring Pulmonary Ventilation During Exercise
- Author
-
Harel, G, primary, Reuveni, R, additional, Segel, M, additional, Inbar, O, additional, Dubnov-Raz, G, additional, and Scheinowitz, M, additional
- Published
- 2021
- Full Text
- View/download PDF
4. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection
- Author
-
Venkatesan, S, Myles, PR, Bolton, KJ, Muthuri, SG, Al Khuwaitir, T, Anovadiya, AP, Azziz-Baumgartner, E, Bajjou, T, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, VH, Burgmann, H, Cao, B, Carratala, J, Chinbayar, T, Cilloniz, C, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Fanella, S, Gao, Z, Gerardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoeger, PH, Hu, XY, Islam, QT, Jimenez, MF, Keijzers, G, Khalili, H, Kusznierz, G, Kuzman, I, Langenegger, E, Lankarani, KB, Leo, Y-S, Libster, RP, Linko, R, Madanat, F, Maltezos, E, Mamun, A, Manabe, T, Metan, G, Mickiene, A, Mikic, D, Mohn, KG, Oliva, ME, Ozkan, M, Parekh, D, Paul, M, Rath, BA, Refaey, S, Rodriguez, AH, Sertogullarindan, B, Skret-Magierlo, J, Somer, A, Talarek, E, Tang, JW, To, K, Dat, T, Uyeki, TM, Vaudry, W, Vidmar, T, Zarogoulidis, P, Nguyen-Van-Tam, JS, Venkatesan, S, Myles, PR, Bolton, KJ, Muthuri, SG, Al Khuwaitir, T, Anovadiya, AP, Azziz-Baumgartner, E, Bajjou, T, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, VH, Burgmann, H, Cao, B, Carratala, J, Chinbayar, T, Cilloniz, C, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Fanella, S, Gao, Z, Gerardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoeger, PH, Hu, XY, Islam, QT, Jimenez, MF, Keijzers, G, Khalili, H, Kusznierz, G, Kuzman, I, Langenegger, E, Lankarani, KB, Leo, Y-S, Libster, RP, Linko, R, Madanat, F, Maltezos, E, Mamun, A, Manabe, T, Metan, G, Mickiene, A, Mikic, D, Mohn, KG, Oliva, ME, Ozkan, M, Parekh, D, Paul, M, Rath, BA, Refaey, S, Rodriguez, AH, Sertogullarindan, B, Skret-Magierlo, J, Somer, A, Talarek, E, Tang, JW, To, K, Dat, T, Uyeki, TM, Vaudry, W, Vidmar, T, Zarogoulidis, P, and Nguyen-Van-Tam, JS
- Abstract
BACKGROUND: The effect of neuraminidase inhibitor (NAI) treatment on length of stay (LoS) in patients hospitalized with influenza is unclear. METHODS: We conducted a one-stage individual participant data (IPD) meta-analysis exploring the association between NAI treatment and LoS in patients hospitalized with 2009 influenza A(H1N1) virus (A[H1N1]pdm09) infection. Using mixed-effects negative binomial regression and adjusting for the propensity to receive NAI, antibiotic, and corticosteroid treatment, we calculated incidence rate ratios (IRRs) and 95% confidence intervals (CIs). Patients with a LoS of <1 day and those who died while hospitalized were excluded. RESULTS: We analyzed data on 18 309 patients from 70 clinical centers. After adjustment, NAI treatment initiated at hospitalization was associated with a 19% reduction in the LoS among patients with clinically suspected or laboratory-confirmed influenza A(H1N1)pdm09 infection (IRR, 0.81; 95% CI, .78-.85), compared with later or no initiation of NAI treatment. Similar statistically significant associations were seen in all clinical subgroups. NAI treatment (at any time), compared with no NAI treatment, and NAI treatment initiated <2 days after symptom onset, compared with later or no initiation of NAI treatment, showed mixed patterns of association with the LoS. CONCLUSIONS: When patients hospitalized with influenza are treated with NAIs, treatment initiated on admission, regardless of time since symptom onset, is associated with a reduced LoS, compared with later or no initiation of treatment.
- Published
- 2020
5. Osteocalcin is independently associated with body mass index in adolescent girls
- Author
-
Dubnov-Raz, G., Ish-Shalom, S., Chodick, G., Rozen, G. S., Giladi, A., and Constantini, N. W.
- Published
- 2012
- Full Text
- View/download PDF
6. Influence of water drinking on resting energy expenditure in overweight children
- Author
-
Dubnov-Raz, G, Constantini, N W, Yariv, H, Nice, S, and Shapira, N
- Published
- 2011
- Full Text
- View/download PDF
7. Dietary treatment of obesity - a chronicle of failure?: T5:RS3.1
- Author
-
Berry, E M and Dubnov-Raz, G
- Published
- 2011
8. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an IPD meta-analysis
- Author
-
Muthuri, SG, Venkatesan, S, Myles, PR, Leonardi-Bee, J, Lim, WS, Mamun, AA, Anovadiya, AP, Araújo, WN, Azziz-Baumgartner, E, Báez, C, Bantar, C, Barhoush, MM, Bassetti, M, Beovic, B, Bingisser, R, Bonmarin, I, Borja-Aburto, VH, Cao, B, Carratala, J, Cuezzo, MR, Denholm, JT, Dominguez, SR, Duarte, PA, Dubnov-Raz, G, Echavarria, M, Fanella, S, Fraser, J, Gao, Z, Gérardin, P, Giannella, M, Gubbels, S, Herberg, J, Iglesias, AL, Hoeger, PH, Hoffmann, M, Hu, X, Islam, QT, Jiménez, MF, Kandeel, A, Keijzers, G, Khalili, H, Khandaker, G, Knight, M, Kusznierz, G, Kuzman, I, Kwan, AM, Amine, IL, Langenegger, E, Lankarani, KB, Leo, YS, Linko, R, Liu, P, Madanat, F, Manabe, T, Mayo-Montero, E, McGeer, A, Memish, ZA, Metan, G, Mikić, D, Mohn, KG, Moradi, A, Nymadawa, P, Ozbay, B, Ozkan, M, Parekh, D, Paul, M, Poeppl, W, Polack, FP, Rath, BA, Rodríguez, AH, Siqueira, MM, Skręt-Magierło, J, Talarek, E, Tang, JW, Torres, A, Törün, SH, Tran, D, Uyeki, TM, Van Zwol, A, Vaudry, W, Velyvyte, D, Vidmar, T, Zarogoulidis, P, PRIDE Consortium Investigators, and Nguyen-Van-Tam, JS
- Subjects
1117 Public Health And Health Services ,hospitalisation ,Virology ,individual participant data meta-analyses ,1103 Clinical Sciences ,Influenza-related pneumonia ,neuraminidase inhibitors ,PRIDE Consortium Investigators - Published
- 2015
9. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis
- Author
-
Muthuri, SG, Venkatesan, S, Myles, PR, Leonardi-Bee, J, Lim, WS, Al Mamun, A, Anovadiya, AP, Araujo, WN, Azziz-Baumgartner, E, Baez, C, Bantar, C, Barhoush, MM, Bassetti, M, Beovic, B, Bingisser, R, Bonmarin, I, Borja-Aburto, VH, Cao, B, Carratala, J, Cuezzo, MR, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Echavarria, M, Fanella, S, Fraser, J, Gao, Z, Gerardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoeger, PH, Hoffmann, M, Hu, X, Islam, QT, Jimenez, MF, Kandeel, A, Keijzers, G, Khalili, H, Khandaker, G, Knight, M, Kusznierz, G, Kuzman, I, Kwan, AMC, Lahlou Amine, I, Langenegger, E, Lankarani, KB, Leo, Y-S, Linko, R, Liu, P, Madanat, F, Manabe, T, Mayo-Montero, E, McGeer, A, Memish, ZA, Metan, G, Mikic, D, Mohn, KGI, Moradi, A, Nymadawa, P, Ozbay, B, Ozkan, M, Parekh, D, Paul, M, Poeppl, W, Polack, FP, Rath, BA, Rodriguez, AH, Siqueira, MM, Skret-Magierlo, J, Talarek, E, Tang, JW, Torres, A, Torun, SH, Tran, D, Uyeki, TM, van Zwol, A, Vaudry, W, Velyvyte, D, Vidmar, T, Zarogoulidis, P, Nguyen-Van-Tam, JS, Muthuri, SG, Venkatesan, S, Myles, PR, Leonardi-Bee, J, Lim, WS, Al Mamun, A, Anovadiya, AP, Araujo, WN, Azziz-Baumgartner, E, Baez, C, Bantar, C, Barhoush, MM, Bassetti, M, Beovic, B, Bingisser, R, Bonmarin, I, Borja-Aburto, VH, Cao, B, Carratala, J, Cuezzo, MR, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Echavarria, M, Fanella, S, Fraser, J, Gao, Z, Gerardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoeger, PH, Hoffmann, M, Hu, X, Islam, QT, Jimenez, MF, Kandeel, A, Keijzers, G, Khalili, H, Khandaker, G, Knight, M, Kusznierz, G, Kuzman, I, Kwan, AMC, Lahlou Amine, I, Langenegger, E, Lankarani, KB, Leo, Y-S, Linko, R, Liu, P, Madanat, F, Manabe, T, Mayo-Montero, E, McGeer, A, Memish, ZA, Metan, G, Mikic, D, Mohn, KGI, Moradi, A, Nymadawa, P, Ozbay, B, Ozkan, M, Parekh, D, Paul, M, Poeppl, W, Polack, FP, Rath, BA, Rodriguez, AH, Siqueira, MM, Skret-Magierlo, J, Talarek, E, Tang, JW, Torres, A, Torun, SH, Tran, D, Uyeki, TM, van Zwol, A, Vaudry, W, Velyvyte, D, Vidmar, T, Zarogoulidis, P, and Nguyen-Van-Tam, JS
- Abstract
BACKGROUND: The impact of neuraminidase inhibitors (NAIs) on influenza-related pneumonia (IRP) is not established. Our objective was to investigate the association between NAI treatment and IRP incidence and outcomes in patients hospitalised with A(H1N1)pdm09 virus infection. METHODS: A worldwide meta-analysis of individual participant data from 20 634 hospitalised patients with laboratory-confirmed A(H1N1)pdm09 (n = 20 021) or clinically diagnosed (n = 613) 'pandemic influenza'. The primary outcome was radiologically confirmed IRP. Odds ratios (OR) were estimated using generalised linear mixed modelling, adjusting for NAI treatment propensity, antibiotics and corticosteroids. RESULTS: Of 20 634 included participants, 5978 (29·0%) had IRP; conversely, 3349 (16·2%) had confirmed the absence of radiographic pneumonia (the comparator). Early NAI treatment (within 2 days of symptom onset) versus no NAI was not significantly associated with IRP [adj. OR 0·83 (95% CI 0·64-1·06; P = 0·136)]. Among the 5978 patients with IRP, early NAI treatment versus none did not impact on mortality [adj. OR = 0·72 (0·44-1·17; P = 0·180)] or likelihood of requiring ventilatory support [adj. OR = 1·17 (0·71-1·92; P = 0·537)], but early treatment versus later significantly reduced mortality [adj. OR = 0·70 (0·55-0·88; P = 0·003)] and likelihood of requiring ventilatory support [adj. OR = 0·68 (0·54-0·85; P = 0·001)]. CONCLUSIONS: Early NAI treatment of patients hospitalised with A(H1N1)pdm09 virus infection versus no treatment did not reduce the likelihood of IRP. However, in patients who developed IRP, early NAI treatment versus later reduced the likelihood of mortality and needing ventilatory support.
- Published
- 2016
10. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
- Author
-
Muthuri, SG, Venkatesan, S, Myles, PR, Leonardi-Bee, J, Al Khuwaitir, TSA, Al Mamun, A, Anovadiya, AP, Azziz-Baumgartner, E, Báez, C, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, VH, Burgmann, H, Cao, B, Carratala, J, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Echavarria, M, Fanella, S, Gao, Z, Gérardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoger, PH, Hu, X, Islam, QT, Jiménez, MF, Kandeel, A, Keijzers, G, Khalili, H, Knight, M, Kudo, K, Kusznierz, G, Kuzman, I, Kwan, AMC, Amine, IL, Langenegger, E, Lankarani, KB, Leo, Y-S, Linko, R, Liu, P, Madanat, F, Mayo-Montero, E, McGeer, A, Memish, Z, Metan, G, Mickiene, A, Mikic, D, Mohn, KGI, Moradi, A, Nymadawa, P, Oliva, ME, Ozkan, M, Parekh, D, Paul, M, Polack, FP, Rath, BA, Rodríguez, AH, Sarrouf, EB, Seale, AC, Sertogullarindan, B, Siqueira, MM, Skret-Magierlo, J, Stephan, F, Talarek, E, Tang, JW, To, KKW, Torres, A, Törün, SH, Tran, D, Uyeki, TM, van Zwol, A, Vaudry, W, Vidmar, T, Yokota, RTC, Zarogoulidis, P, Nguyen-van-Tam, JS, Aguiar-Oliveira, ML, Al Masri, M, Amin, R, Araújo, WN, Ballester-Orcal, E, Bantar, C, Bao, J, Barhoush, MM, Basher, A, Bautista, E, Bettinger, J, Bingisser, R, Bouza, E, Bozkurt, I, Celjuska-Tošev, E, Chan, KKC, Chen, Y, Chinbayar, T, Cilloniz, C, Cox, RJ, Cuezzo, MR, Cui, W, Dashti-Khavidaki, S, du, B, El Rhaffouli, H, Escobar, H, Florek-Michalska, A, Fraser, J, Gerrard, J, Gormley, S, Götberg, S, Hoffmann, M, Honarvar, B, Hu, J, Kemen, C, Khandaker, G, Koay, KSC, Kojic, M, Kyaw, WM, Leibovici, L, Li, H, Li, X-L, Libster, R, Loh, TP, Macbeth, D, Maltezos, E, Manabe, T, Marcone, DN, Marczynska, M, Mastalir, FP, Moghadami, M, Moriconi, L, Ozbay, B, Pečavar, B, Poeppl, W, Poliquin, PG, Rahman, M, Rascon-Pacheco, A, Refaey, S, Schweiger, B, Smith, FG, Somer, A, Souza, TML, Tabarsi, P, Tripathi, CB, Velyvyte, D, Viasus, D, Yu, Q, Yuen, K-Y, Zhang, W, Zuo, W, Pediatric surgery, CCA - Innovative therapy, Muthuri, Stella G., Venkatesan, Sudhir, Myles, Puja R., Leonardi-Bee, Jo, Al Khuwaitir, Tarig S. A., Al Mamun, Adbullah, Anovadiya, Ashish P., Azziz-Baumgartner, Eduardo, Báez, Clarisa, Bassetti, Matteo, Beovic, Bojana, Bertisch, Barbara, Bonmarin, Isabelle, Booy, Robert, Borja-Aburto, Victor H., Burgmann, Heinz, Cao, Bin, Carratala, Jordi, Denholm, Justin T., Dominguez, Samuel R., Duarte, Pericles A.D., Dubnov-Raz, Gal, Echavarria, Marcela, Fanella, Sergio, Gao, Zhancheng, Gérardin, Patrick, Giannella, Maddalena, Gubbels, Sophie, Herberg, Jethro, Higuera Iglesias, Anjarath L., Hoger, Peter H., Hu, Xiaoyun, Islam, Quazi T., Jiménez, Mirela F., Kandeel, Amr, Keijzers, Gerben, Khalili, Hossein, Knight, Marian, Kudo, Koichiro, Kusznierz, Gabriela, Kuzman, Ilija, Kwan, Arthur M. C., Amine, Idriss Lahlou, Langenegger, Eduard, Lankarani, Kamran B., Leo, Yee-Sin, Linko, Rita, Liu, Pei, Madanat, Fari, Mayo-Montero, Elga, Mcgeer, Allison, Memish, Ziad, Metan, Gokhan, Mickiene, Aukse, Mikic, Dragan, Mohn, Kristin G.I., Moradi, Ahmadreza, Nymadawa, Pagbajabyn, Oliva, Maria E., Ozkan, Mehpare, Parekh, Dhruv, Paul, Mical, Polack, Fernando P., Rath, Barbara A., Rodríguez, Alejandro H., Sarrouf, Elena B., Seale, Anna C., Sertogullarindan, Bunyamin, Siqueira, Marilda M., Skret-Magierlo, Joanna, Stephan, Frank, Talarek, Ewa, Tang, Julian W., To, Kelvin K.W., Torres, Antoni, Törün, Selda H., Tran, Dat, Uyeki, Timothy M., van Zwol, Annelie, Vaudry, Wendy, Vidmar, Tjasa, Yokota, Renata T.C., Zarogoulidis, Paul, Nguyen-van-Tam, Jonathan S, Aguiar-Oliveira, Maria de Lourde, Al Masri, Malakita, Amin, Robed, Araújo, Wildo N., Ballester-Orcal, Elena, Bantar, Carlo, Bao, Jing, Barhoush, Mazen M., Basher, Ariful, Bautista, Edgar, Bettinger, Julie, Bingisser, Roland, Bouza, Emilio, Bozkurt, Ilkay, Celjuska-Tošev, Elvira, Chan, Kenny K.C., Chen, Yusheng, Chinbayar, Tserendorj, Cilloniz, Catia, Cox, Rebecca J., Cuezzo, María R., Cui, Wei, Dashti-Khavidaki, Simin, Du, Bin, El Rhaffouli, Hicham, Escobar, Hernan, Florek-Michalska, Agnieszka, Fraser, Jame, Gerrard, John, Gormley, Stuart, Götberg, Sandra, Hoffmann, Matthia, Honarvar, Behnam, Hu, Jianmin, Kemen, Christoph, Khandaker, Gulam, Koay, Evelyn S. C., Kojic, Miroslav, Kyaw, Win M., Leibovici, Leonard, Li, Hongru, Li, Xiao-Li, Libster, Romina, Loh, Tze P., Macbeth, Deborough, Maltezos, Efstratio, Manabe, Toshie, Marcone, Débora N., Marczynska, Magdalena, Mastalir, Fabiane P., Moghadami, Mohsen, Moriconi, Lilian, Ozbay, Bulent, Pečavar, Blaž, Poeppl, Wolfgang, Poliquin, Philippe G., Rahman, Mahmudur, Rascon-Pacheco, Alberto, Refaey, Samir, Schweiger, Brunhilde, Smith, Fang G., Somer, Ayper, Souza, Thiago M. L., Tabarsi, Payam, Tripathi, Chandrabhanu B., Velyvyte, Daiva, Viasus, Diego, Yu, Qin, Yuen, Kwok-Yung, Zhang, Wei, and Zuo, Wei
- Subjects
Male ,ANTIVIRAL TREATMENT ,IMPACT ,Respiratory System ,CHILDREN ,Neuraminidase inhibitors ,Pandemic influenza ,Mortality ,Meta-analysis ,medicine.disease_cause ,THERAPY ,chemistry.chemical_compound ,Influenza A Virus, H1N1 Subtype ,0302 clinical medicine ,Pandemic ,Influenza A Virus ,Influenza A virus ,Zanamivir ,030212 general & internal medicine ,Enzyme Inhibitors ,Child ,OUTCOMES ,0303 health sciences ,biology ,Neuraminidase inhibitor ,Medicine (all) ,virus diseases ,Middle Aged ,3. Good health ,Hospitalization ,Treatment Outcome ,Female ,Life Sciences & Biomedicine ,Adolescent ,Adult ,Antiviral Agents ,Humans ,Influenza, Human ,Neuraminidase ,Oseltamivir ,Proportional Hazards Models ,Young Adult ,Pandemics ,Pulmonary and Respiratory Medicine ,Human ,medicine.drug ,medicine.medical_specialty ,medicine.drug_class ,PANDEMIC INFLUENZA ,Article ,PRIDE Consortium Investigators ,03 medical and health sciences ,Critical Care Medicine ,General & Internal Medicine ,Internal medicine ,medicine ,H1N1 Subtype ,Intensive care medicine ,Science & Technology ,030306 microbiology ,business.industry ,STEM-CELL TRANSPLANTATION ,ADULTS ,Odds ratio ,Influenza ,chemistry ,RISK-FACTORS ,biology.protein ,business - Abstract
Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection. Methods: We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identified potential data contributors from an earlier systematic review of reported studies addressing the same research question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting for both treatment propensity and potential confounders, using generalised linear mixed modelling. We assessed the association with time to treatment using time-dependent Cox regression shared frailty modelling. Findings: We included data for 29234 patients from 78 studies of patients admitted to hospital between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 0·81; 95% CI 0·70-0·93; p=0·0024). Compared with later treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 0·48; 95% CI 0·41-0·56; p
- Published
- 2014
11. S102 Vitamin d supplementation to prevent acute respiratory infections: systematic review and meta-analysis of individual participant data
- Author
-
Martineau, AR, primary, Jolliffe, DA, additional, Hooper, RL, additional, Greenberg, L, additional, Aloia, JF, additional, Bergman, P, additional, Dubnov-Raz, G, additional, Esposito, S, additional, Ganmaa, D, additional, Goodall, EC, additional, Grant, C, additional, Janssens, W, additional, Laaksi, I, additional, Manaseki-Holland, S, additional, Murdoch, D, additional, Neale, RE, additional, Rees, JR, additional, Simpson, S, additional, Stelmach, I, additional, Kumar, G Trilok, additional, Urashima, M, additional, and Camargo, CA, additional
- Published
- 2016
- Full Text
- View/download PDF
12. High Mid-Flow to Vital Capacity Ratio and the Response to Exercise in Children With Congenital Heart Disease
- Author
-
Vilozni, D., primary, Alcaneses-Ofek, M. R., additional, Reuveny, R., additional, Rosenblum, O., additional, Inbar, O., additional, Katz, U., additional, Ziv-Baran, T., additional, and Dubnov-Raz, G., additional
- Published
- 2016
- Full Text
- View/download PDF
13. Relationship of hyperactivity/inattention with adiposity and lifestyle characteristics in preschool children
- Author
-
Ebenegger, V, Marques-Vidal, P M, Munsch, S, Quartier, V, Nydegger, A, Barral, J, Hartmann, T, Dubnov-Raz, G, Kriemler, S, Puder, J J, University of Zurich, and Ebenegger, V
- Subjects
2728 Neurology (clinical) ,610 Medicine & health ,10060 Epidemiology, Biostatistics and Prevention Institute (EBPI) ,2735 Pediatrics, Perinatology and Child Health - Published
- 2012
- Full Text
- View/download PDF
14. The effect of vitamin C on upper respiratory infections in adolescent swimmers: A randomized trial
- Author
-
University of Helsinki, Hjelt Institute, Constantini, NW, Dubnov-Raz, G, Eyal, BB, Berry, EM, Cohen, AH, Hemilä, Harri, University of Helsinki, Hjelt Institute, Constantini, NW, Dubnov-Raz, G, Eyal, BB, Berry, EM, Cohen, AH, and Hemilä, Harri
- Abstract
The risk of upper respiratory infections (URIs) is increased in people who are under heavy physical stress, including recreational and competitive swimmers. Additional treatment options are needed, especially in the younger age group. The aim of this study was to determine whether 1 g/day vitamin C supplementation affects the rate, length, or severity of URIs in adolescent swimmers. We carried out a randomized, double-blind, placebo-controlled trial during three winter months, among 39 competitive young swimmers (mean age 13.8 ± 1.6 years) in Jerusalem, Israel. Vitamin C had no effect on the incidence of URIs (rate ratio = 1.01; 95% confidence interval (CI) = 0.70-1.46). The duration of respiratory infections was 22% shorter in vitamin C group, but the difference was not statistically significant. However, we found a significant interaction between vitamin C effect and sex, so that vitamin C shortened the duration of infections in male swimmers by 47% (95% CI: -80% to -14%), but had no effect on female swimmers (difference in duration: +17%; 95% CI: -38% to +71%). The effect of vitamin C on the severity of URIs was also different between male and female swimmers, so that vitamin C was beneficial for males, but not for females. Our study indicates that vitamin C does not affect the rate of respiratory infections in competitive swimmers. Nevertheless, we found that vitamin C decreased the duration and severity of respiratory infections in male swimmers, but not in females. This finding warrants further research.
- Published
- 2011
15. Can airway size relative to lung volume (dysynapsis ratio) predict aerobic capacity in children with congenital heart disease?
- Author
-
Alcaneses-Ofek, M.S., primary, Vilozni, D., additional, Reuveny, R., additional, Katz, U., additional, Efrati, O., additional, and Dubnov-Raz, G., additional
- Published
- 2013
- Full Text
- View/download PDF
16. Diet and lifestyle in managing postmenopausal obesity
- Author
-
Dubnov-Raz, G., primary, Pines, A., additional, and Berry, E. M., additional
- Published
- 2007
- Full Text
- View/download PDF
17. High prevalence of vitamin D insufficiency in athletes and dancers.
- Author
-
Constantini NW, Arieli R, Chodick G, and Dubnov-Raz G
- Published
- 2010
- Full Text
- View/download PDF
18. Obsessive compulsive symptomatology in female adolescent inpatients with restrictive compared to binge-purge eating disorders
- Author
-
Stein, D., Lewis, Y., Mann, T. Gilon, Enoch-Levy, A., Dubnov-Raz, G., Gothelf, D., and Abraham Weizman
19. Causes of sudden death during the triathlon.
- Author
-
Constantini NW, Dubnov-Raz G, Mountjoy M, Constantini, Naama W, Dubnov-Raz, Gal, and Mountjoy, Margo
- Published
- 2010
- Full Text
- View/download PDF
20. Physical activity is associated with increased bone mass in female adolescents despite vitamin D deficiency.
- Author
-
Constantini N, Dubnov-Raz G, Chodik G, Rozen GS, Giladi A, and Ish-Shalom S
- Published
- 2008
21. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection
- Author
-
Venkatesan, Sudhir, Myles, Puja R, Bolton, Kirsty J, Muthuri, Stella G, Al Khuwaitir, Tarig, Anovadiya, Ashish P, Azziz-Baumgartner, Eduardo, Bajjou, Tahar, Bassetti, Matteo, Beovic, Bojana, Bertisch, Barbara, Bonmarin, Isabelle, Booy, Robert, Borja-Aburto, Victor H, Burgmann, Heinz, Cao, Bin, Carratala, Jordi, Chinbayar, Tserendorj, Cilloniz, Catia, Denholm, Justin T, Dominguez, Samuel R, Duarte, Pericles A D, Dubnov-Raz, Gal, Fanella, Sergio, Gao, Zhancheng, Gérardin, Patrick, Giannella, Maddalena, Gubbels, Sophie, Herberg, Jethro, Higuera Iglesias, Anjarath Lorena, Hoeger, Peter H, Hu, Xiao Yun, Islam, Quazi T, Jiménez, Mirela F, Keijzers, Gerben, Khalili, Hossein, Kusznierz, Gabriela, Kuzman, Ilija, Langenegger, Eduard, Lankarani, Kamran B, Leo, Yee-Sin, Libster, Romina P, Linko, Rita, Madanat, Faris, Maltezos, Efstratios, Mamun, Abdullah, Manabe, Toshie, Metan, Gokhan, Mickiene, Auksė, Mikić, Dragan, Mohn, Kristin G I, Oliva, Maria E, Ozkan, Mehpare, Parekh, Dhruv, Paul, Mical, Rath, Barbara A, Refaey, Samir, Rodríguez, Alejandro H, Sertogullarindan, Bunyamin, Skręt-Magierło, Joanna, Somer, Ayper, Talarek, Ewa, Tang, Julian W, To, Kelvin, Tran, Dat, Uyeki, Timothy M, Vaudry, Wendy, Vidmar, Tjasa, Zarogoulidis, Paul, Nguyen-Van-Tam, Jonathan S, PRIDE Consortium Investigators, Imperial College London, HUS Perioperative, Intensive Care and Pain Medicine, Department of Diagnostics and Therapeutics, Clinicum, Venkatesan S., Myles P.R., Bolton K.J., Muthuri S.G., Al Khuwaitir T., Anovadiya A.P., Azziz-Baumgartner E., Bajjou T., Bassetti M., Beovic B., Bertisch B., Bonmarin I., Booy R., Borja-Aburto V.H., Burgmann H., Cao B., Carratala J., Chinbayar T., Cilloniz C., Denholm J.T., Dominguez S.R., Duarte P.A.D., Dubnov-Raz G., Fanella S., Gao Z., Gerardin P., Giannella M., Gubbels S., Herberg J., Higuera Iglesias A.L., Hoeger P.H., Hu X.Y., Islam Q.T., Jimenez M.F., Keijzers G., Khalili H., Kusznierz G., Kuzman I., Langenegger E., Lankarani K.B., Leo Y.-S., Libster R.P., Linko R., Madanat F., Maltezos E., Mamun A., Manabe T., Metan G., Mickiene A., Mikic D., Mohn K.G.I., Oliva M.E., Ozkan M., Parekh D., Paul M., Rath B.A., Refaey S., Rodriguez A.H., Sertogullarindan B., Skret-Magierlo J., Somer A., Talarek E., Tang J.W., To K., Tran D., Uyeki T.M., Vaudry W., Vidmar T., Zarogoulidis P., and Nguyen-Van-Tam J.S.
- Subjects
0301 basic medicine ,Male ,pandemic influenza ,OSELTAMIVIR TREATMENT ,IMPACT ,Neuraminidase/antagonists & inhibitors ,CHILDREN ,medicine.disease_cause ,0302 clinical medicine ,antivirals ,Influenza A Virus, H1N1 Subtype ,Adrenal Cortex Hormones ,IPD meta-analysi ,Influenza A virus ,Immunology and Allergy ,030212 general & internal medicine ,IPD meta-analysis ,Young adult ,Enzyme Inhibitors ,Child ,11 Medical and Health Sciences ,RISK ,11832 Microbiology and virology ,Antiviral Agents/therapeutic use ,OUTCOMES ,COMPLICATIONS ,biology ,Neuraminidase inhibitor ,Enzyme inhibitors ,Middle Aged ,Antivirals ,antiviral ,3. Good health ,Anti-Bacterial Agents ,Infectious Diseases ,Treatment Outcome ,Meta-analysis ,Cohort ,Viruses ,Enzyme Inhibitors/pharmacology/therapeutic use ,Female ,Pandemic influenza ,Adult ,medicine.medical_specialty ,Adolescent ,medicine.drug_class ,030106 microbiology ,IPD meta-analysis, Neuraminidase inhibitors, antivirals, length of stay, pandemic influenza ,Neuraminidase ,Adrenal Cortex Hormones/therapeutic use ,Microbiology ,Antiviral Agents ,PRIDE Consortium Investigators ,Grip ,03 medical and health sciences ,Major Articles and Brief Reports ,Young Adult ,Pharmacotherapy ,Internal medicine ,Influenza, Human ,medicine ,Humans ,COHORT ,Pandemics ,ddc:613 ,Aged ,Neuraminidase inhibitors ,business.industry ,CLINICAL-FEATURES ,ADULTS ,06 Biological Sciences ,Influenza, Human/drug therapy/epidemiology ,Length of Stay ,Confidence interval ,Influenza ,Editor's Choice ,Anti-Bacterial Agents/therapeutic use ,Inhibidors enzimàtics ,3121 General medicine, internal medicine and other clinical medicine ,biology.protein ,business ,RESISTANCE - Abstract
Background The effect of neuraminidase inhibitor (NAI) treatment on length of stay (LoS) in patients hospitalized with influenza is unclear. Methods We conducted a one-stage individual participant data (IPD) meta-analysis exploring the association between NAI treatment and LoS in patients hospitalized with 2009 influenza A(H1N1) virus (A[H1N1]pdm09) infection. Using mixed-effects negative binomial regression and adjusting for the propensity to receive NAI, antibiotic, and corticosteroid treatment, we calculated incidence rate ratios (IRRs) and 95% confidence intervals (CIs). Patients with a LoS of, We found that neuraminidase inhibitor (NAI) treatment initiated on hospital admission to patients with clinically diagnosed or laboratory-confirmed A(H1N1)pdm09 virus infection was associated with a reduction in hospital length of stay when compared to later or no NAI treatment.
- Published
- 2018
22. Can placing posters increase awareness to pediatric obesity in a Pediatric Emergency Department?
- Author
-
Inbar A, Friedman N, and Dubnov-Raz G
- Abstract
Background: Identification and addressing of pediatric obesity are the first steps in its management, and Pediatric Emergency Department (PED) visits have a potential to increase its awareness. The main aim of this study was to examine if posters placed in the PED alerting to obesity increased its documentation., Methods: The design of this paper is that of an interventional study which took place at a large tertiary PED during May-August 2022. Obesity listing in PED charts of children with obesity was defined as weight percentile >90 and examined over two weeks before poster placement, during four weeks of display, and for four weeks after their removal. Logistic mixed models were used to examine the associations between several factors and obesity documentation., Results: During the whole study period, there were 4174 PED visits of children aged >2 that had body weight data, of which 590 (14.2%) had obesity. Obesity addressing in charts of children with obesity was found in 2/134 (1.5%) before poster placement, 7/229 (3.1%) during placement, and 10/227 (4.4%) after removal, but this 2-3-fold increase was not statistically significant (P=0.313). There were only 28 scans of a QR code on the poster that offered obesity treatment options, and only two parents filled its questionnaire., Conclusions: Poster placement could possibly improve obesity discussion in the PED, yet larger samples and additional techniques are needed.
- Published
- 2024
- Full Text
- View/download PDF
23. Using weight-for-age as a screening tool for metabolic syndrome in apparently healthy adolescents.
- Author
-
Oselka N, Dubnov-Raz G, and Ziv-Baran T
- Abstract
Background: The increasing prevalence of metabolic syndrome (MetS) among adolescents necessitates a simple and easy-to-use screening tool. This study aimed to develop and validate a simple model based on age, sex, race, and weight-for-age or BMI-for-age to identify adolescents with MetS., Methods: A cross-sectional study of adolescents (aged 12-18 years) who participated in the American National Health and Nutrition Examination Survey (NHANES) was performed. Participants with pre-existing hypertension, diabetes or dyslipidemia were excluded. Data from 2005-2018 were randomly divided into training (70%) and validation (30%) sets. Anthropometric, demographic data, and MetS criteria were extracted., Results: The training group included 1974 adolescents (52% boys, median age 15 years), and the validation group included 848 adolescents (50% boys, median age 14 years). Both weight- and BMI-for-age demonstrated good discrimination ability in the training group (AUC = 0.897 and 0.902, respectively), with no significant difference between them (p = 0.344). Multivariable models showed similar discrimination ability. Therefore, weight-for-age was chosen and using Youden's index, the 93rd weight-for-age percentile (SDS 1.5) was identified as the optimal cut-off value for MetS. Similar values were observed in the validation group., Conclusions: Among adolescents aged 12-18 years, weight-for-age percentiles are an easy-to-use primary screening indicator for the presence of MetS., Impact: The prevalence of metabolic syndrome in adolescents is increasing. An early detection screening tool is required to prevent related adulthood morbidity. Screening adolescents for metabolic syndrome is challenging. This study suggests the use of weight-for-age as a single criterion for primary screening of adolescents aged 12-18. Using weight-for-age as a single predictor of metabolic syndrome is expected to increase screening rates compared to using BMI-for-age, due to its simplicity., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
24. Comparison of a Telehealth-Based Intensive Treatment Program with a Rewarding App vs. On-Site Care for Youth with Obesity: A Historical Cohort Study.
- Author
-
Sela Peremen K, Maor S, Yaniv A, Aloni I, Ziv-Baran T, and Dubnov-Raz G
- Abstract
The recommended treatment for children with obesity includes numerous consultations by a multidisciplinary team, which is very cumbersome. Telehealth can assist in administering frequent care to children with obesity, yet the exact approaches and modes of delivery are still explored. During the COVID-19 pandemic, we developed an intensive telehealth-based treatment program that included a rewarding app for children with obesity. The aim of this study was to compare 6-month changes in body mass index (BMI) and body fat percent between participants in the program ( n = 70) vs. children that underwent historic on-site care ( n = 87). After 6 months, more participants in the telehealth group continued treatment compared to the on-site group (79% vs. 60%, p < 0.001). A significant reduction in the median BMI z-score (zBMI) was seen after 6 months in both groups ( p < 0.01), with a similar proportion of zBMI reductions (71% in the telehealth group, 75% in the comparison group, p = 0.76). No statistically significant differences were found between the study groups in 6-month changes in BMI, zBMI, body fat percent or fat z-scores. We conclude that our telehealth program, which was executed during the COVID-19 pandemic, resulted in a high proportion of children with zBMI reduction that was comparable with the more personal on-site care.
- Published
- 2023
- Full Text
- View/download PDF
25. Obesity screening in the pediatric emergency department - A missed opportunity?
- Author
-
Friedman N, Erez-Granat O, Inbar A, and Dubnov-Raz G
- Abstract
Objectives: There is a low rate of body mass index measurements and obesity screening in primary pediatric care. Pediatric emergency department (PED) visits, with their large volumes and routine weight measurements, provide a unique opportunity to identify and address obesity. The study objectives were to examine the rate of addressing obesity in the PED and to identify its predicting factors., Methods: From electronic medical records of PED visits during 2010-2019, we extracted data on age, gender, weight, time, listed diagnoses, and discharge texts. The primary outcome was a listed diagnosis of "obesity" on discharge letters of children with obesity. Secondary outcomes were addressing weight in the discharge letter and written recommendations for obesity-related treatment. Mixed models were used to test for associations between each of the three outcomes and patient/visit characteristics., Results: There were 150,250 PED visits by 88,253 different children and adolescents. Obesity was found in 10,691 children (12.1%). Among these, listed "obesity" diagnosis was present in only 240 (1.5%) visits. Text addressing overweight/obesity was recorded in 721 (4.4%) visits, and weight-related recommendations were documented in 716 (4.4%) visits. "Obesity" was documented in females more often than in males, in older children, in children with higher weights, and in visits conducted during the mornings., Conclusions: The rate of obesity diagnosis in the PED was extremely low, hence the potential screening ability of the PED in this matter is highly under-utilized. PEDs could increase the recognition of obesity, thus assisting in the global efforts in tackling this disease., Competing Interests: The authors declare no competing interests., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
26. Pediatric obesity and body weight following the COVID-19 pandemic.
- Author
-
Dubnov-Raz G, Maor S, and Ziv-Baran T
- Subjects
- Body Mass Index, Body Weight, Child, Communicable Disease Control, Female, Humans, Male, Overweight epidemiology, Pandemics, COVID-19 epidemiology, Pediatric Obesity epidemiology
- Abstract
Background: The SARS-CoV-19 pandemic and its associated lockdowns affected children's lifestyle dramatically. The effect of such changes on children's weight and obesity status is unknown. The aim of this study was to compare body weight and obesity rates in children from before the pandemic to 6 months after the major periods of lockdowns in Israel., Methods: We used data from medical records of pediatric emergency department visits, where weight is routinely measured, to compare weight and obesity prevalence in the fourth quartile of 2020 (n = 2468) as compared with the fourth quartiles of 2018-2019 (n = 5300). Weight was transformed to age- and sex-specific standard-deviation-scores (SDS) for analysis., Results: Weight-SDS increased by a mean of 0.07 during the first 6 months of the pandemic, yet this was only significant in preschoolers. Obesity rates also increased in this age group only, by 37%, from 8.1% to 11.1% (p = 0.01)., Conclusions: Weight-SDS and obesity prevalence increased during the SARS-CoV-19 pandemic, yet only in younger children. Additional studies from other populations are needed., (© 2021 John Wiley & Sons, Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
27. Characteristics of Second-Line Investigations of Middle-Aged Athletes Who Failed Preparticipation Examinations.
- Author
-
Neuman G, Milman A, Ziv-Baran T, and Dubnov-Raz G
- Subjects
- Athletes, Electrocardiography, Exercise Test, Humans, Middle Aged, Surveys and Questionnaires, Physical Examination, Sports
- Abstract
Objective: The role of exercise testing during preparticipation examinations (PPEs) of middle-aged athletes is uncertain. This study examined the characteristics of disqualifications after an initial PPE that includes an exercise test in competitive athletes older than 30 years. We investigated disqualification rates and reasons, second-line investigations performed, and final decisions regarding competitive sports participation., Design: Chart review., Setting: Sports medicine clinic., Participants: Athletes aged >30 years that performed an exercise test as part of their annual PPE at our sports medicine clinic (n = 866)., Independent Variables: Age, sex, height, weight, sport type, cardiovascular risk factors, and abnormal PPE findings., Main Outcome Measures: Additional investigations performed, approval/disqualification regarding competitive sports participation., Results: The initial disqualification rate of athletes was 9.8%. Three (3.6%) athletes were disqualified following questionnaire and physical examination, 19 (22.4%) because of resting electrocardiogram findings, and 65 (76.5%) following the exercise test. After additional work-up, only 5 athletes (0.4%) were ultimately found ineligible for competitive sports. From those, only 2 athletes (0.2%) were disqualified because of exercise test findings, which were episodes of supraventricular tachycardia and not ischemia-related., Conclusions: The addition of an exercise test to the PPE of middle-aged athletes is of limited value. If exercise testing of older athletes is performed, arrhythmias are probably of higher significance than ST-T changes., Competing Interests: The authors report no conflicts of interest., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
28. Age Differences in Recovery Rate Following an Aerobic-Based Exercise Protocol Inducing Muscle Damage Among Amateur, Male Athletes.
- Author
-
Markus I, Constantini K, Goldstein N, Amedi R, Bornstein Y, Stolkovsky Y, Vidal M, Lev-Ari S, Balaban R, Leibou S, Blumenfeld-Katzir T, Ben-Eliezer N, Peled D, Assaf Y, Jensen D, Constantini N, Dubnov-Raz G, Halperin I, and Gepner Y
- Abstract
Purpose: Compare recovery rates between active young (Y) and middle-aged (MA) males up to 48H post aerobically based, exercise-induced muscle damage (EIMD) protocol. A secondary aim was to explore the relationships between changes in indices associated with EIMD and recovery throughout this timeframe. Methods: Twenty-eight Y ( n = 14, 26.1 ± 2.9y, 74.5 ± 9.3 kg) and MA ( n = 14, 43.6 ± 4.1y, 77.3 ± 12.9 kg) physically active males, completed a 60-min downhill running (DHR) on a treadmill at -10% incline and at 65% of maximal heart rate (HR). Biochemical, biomechanical, psychological, force production and muscle integrity (using MRI diffusion tensor imaging) markers were measured at baseline, immediately-post, and up to 48H post DHR. Results: During the DHR, HR was lower ( p < 0.05) in MA compared to Y, but running pace and distance covered were comparable between groups. No statistical or meaningful differences were observed between groups for any of the outcomes. Yet, Significant ( p < 0.05) time-effects within each group were observed: markers of muscle damage, cadence and perception of pain increased, while TNF-a, isometric and dynamic force production and stride-length decreased. Creatine-kinase at 24H-post and 48H-post were correlated ( p < 0.05, r range = -0.57 to 0.55) with pain perception, stride-length, and cadence at 24H-post and 48H-post. Significant ( p < 0.05) correlations were observed between isometric force production at all time-points and IL-6 at 48H-post DHR ( r range = -0.62 to (-0.74). Conclusion: Y and MA active male amateur athletes recover in a comparable manner following an EIMD downhill protocol. These results indicate that similar recovery strategies can be used by trainees from both age groups following an aerobic-based EIMD protocol., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Markus, Constantini, Goldstein, Amedi, Bornstein, Stolkovsky, Vidal, Lev-Ari, Balaban, Leibou, Blumenfeld-Katzir, Ben-Eliezer, Peled, Assaf, Jensen, Constantini, Dubnov-Raz, Halperin and Gepner.)
- Published
- 2022
- Full Text
- View/download PDF
29. Epidemiology of childhood fractures in Israel during 2000-2019.
- Author
-
Zacay G, Dubnov-Raz G, Modan-Moses D, Tripto-Shkolnik L, and Levy-Shraga Y
- Subjects
- Adolescent, Arabs, Child, Female, Humans, Incidence, Israel epidemiology, Jews, Male, Fractures, Bone epidemiology
- Abstract
Background: Differences have been reported in incidence rates of fractures in the pediatric population, between countries and over time. The aim of this study was to evaluate the incidence and characteristics of fractures over 20 years among Israeli children., Methods: Incidence rates of fractures were derived from the electronic database of Meuhedet Health Services, a health maintenance organization providing healthcare services to 1.2 million people in Israel. Demographic and clinical data were extracted of all the fractures in individuals aged <18 years during 2000-2019. Fracture sites were determined according to ICD9 definitions. Fracture data were analyzed by age, sex, season and sector (general Jewish population, ultra-orthodox Jews and Arabs)., Results: During the study period 188,283 fractures occurred in 142,049 individuals. The most common were fractures of the upper limb (65%), followed by fractures of the lower limb [20%]. The overall fracture rate was 251 per 10,000 person- years (PY), and was higher for boys than girls (319 vs. 180 per 10,000 PY, p < 0.001). During 20 years, standardized fracture rates decreased significantly in the general Jewish population, among both boys (from 457 to 325 per 10,000 PY, p < 0.001) and girls (from 244 to 196 per 10,000 PY, p < 0.001); increased among ultra-orthodox Jewish boys (from 249 to 285 per 10,000 PY, p = 0.002) and girls (from 147 to 194 per 10,000 PY, p < 0.001); and did not change significantly among Arab boys and girls. The fracture rate peaked among girls aged 10-11 years and among boys aged 12-13 years. Seasonal variation showed a bimodal distribution with peaks during spring and autumn., Conclusions: The incidence of pediatric fractures is affected by age, gender, sector and season. Recognition of fracture characteristics may help identify specific populations and conditions for targeted prevention strategies., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2022
- Full Text
- View/download PDF
30. A Cross-Cultural Examination of Parental Knowledge of Concussion in Three Countries.
- Author
-
Moser RS, Friedman S, Hensel GL, Dubnov-Raz G, and Schatz P
- Subjects
- Adolescent, Athletes, Child, Child, Preschool, Cross-Cultural Comparison, Humans, Parents, United States, Athletic Injuries diagnosis, Brain Concussion diagnosis, Soccer
- Abstract
The aim of the present study was to examine and compare knowledge regarding concussion among parents of youth soccer players, ages 5-17, from the United States, Israel, and Sicily. Results revealed parents from the United States were more knowledgeable than Israeli and Sicilian parents and were more likely to have a previous history of concussion in their children, themselves, and their social contacts. The success of concussion education, programming, and legislation in the US may account for the greater knowledge of US parents and is reason to advocate for similar resources for youth athletes internationally.
- Published
- 2021
- Full Text
- View/download PDF
31. Associations Between Maternal Depression, Antidepressant Use During Pregnancy, and Adverse Pregnancy Outcomes: An Individual Participant Data Meta-analysis.
- Author
-
Vlenterie R, van Gelder MMHJ, Anderson HR, Andersson L, Broekman BFP, Dubnov-Raz G, El Marroun H, Ferreira E, Fransson E, van der Heijden FMMA, Holzman CB, Kim JJ, Khashan AS, Kirkwood BR, Kuijpers HJH, Lahti-Pulkkinen M, Mason D, Misra D, Niemi M, Nordeng HME, Peacock JL, Pickett KE, Prady SL, Premji SS, Räikkönen K, Rubertsson C, Sahingoz M, Shaikh K, Silver RK, Slaughter-Acey J, Soremekun S, Stein DJ, Sundström-Poromaa I, Sutter-Dallay AL, Tiemeier H, Uguz F, Varela P, Vrijkotte TGM, Winterfeld U, Zar HJ, Zervas IM, Prins JB, Pop-Purceleanu M, and Roeleveld N
- Subjects
- Adult, Antidepressive Agents therapeutic use, Apgar Score, Birth Weight, Depression epidemiology, Female, Gestational Age, Humans, Infant, Low Birth Weight, Infant, Newborn, Infant, Small for Gestational Age, Pregnancy, Pregnancy Complications epidemiology, Premature Birth epidemiology, Selective Serotonin Reuptake Inhibitors adverse effects, Antidepressive Agents adverse effects, Depression drug therapy, Pregnancy Complications drug therapy, Pregnancy Outcome epidemiology
- Abstract
Objective: To evaluate the associations of depressive symptoms and antidepressant use during pregnancy with the risks of preterm birth, low birth weight, small for gestational age (SGA), and low Apgar scores., Data Sources: MEDLINE, EMBASE, ClinicalTrials.gov, and PsycINFO up to June 2016., Methods of Study Selection: Data were sought from studies examining associations of depression, depressive symptoms, or use of antidepressants during pregnancy with gestational age, birth weight, SGA, or Apgar scores. Authors shared the raw data of their studies for incorporation into this individual participant data meta-analysis., Tabulation, Integration, and Results: We performed one-stage random-effects meta-analyses to estimate odds ratios (ORs) with 95% CIs. The 215 eligible articles resulted in 402,375 women derived from 27 study databases. Increased risks were observed for preterm birth among women with a clinical diagnosis of depression during pregnancy irrespective of antidepressant use (OR 1.6, 95% CI 1.2-2.1) and among women with depression who did not use antidepressants (OR 2.2, 95% CI 1.7-3.0), as well as for low Apgar scores in the former (OR 1.5, 95% CI 1.3-1.7), but not the latter group. Selective serotonin reuptake inhibitor (SSRI) use was associated with preterm birth among women who used antidepressants with or without restriction to women with depressive symptoms or a diagnosis of depression (OR 1.6, 95% CI 1.0-2.5 and OR 1.9, 95% CI 1.2-2.8, respectively), as well as with low Apgar scores among women in the latter group (OR 1.7, 95% CI 1.1-2.8)., Conclusion: Depressive symptoms or a clinical diagnosis of depression during pregnancy are associated with preterm birth and low Apgar scores, even without exposure to antidepressants. However, SSRIs may be independently associated with preterm birth and low Apgar scores., Systematic Review Registration: PROSPERO, CRD42016035711., Competing Interests: Financial Disclosure Hanan El Marroun disclosed that she received a NARSAD Young Investigator Grant 27853 from the Brain & Behavior Research Foundation. Money was paid to her institution under grant agreement 733206 (LifeCycle) from the European Union's Horizon 2020 Research and Innovation Program and from Erasmus University Rotterdam Fellowship 2014. They also disclosed receiving funding from Stichting Volksbond Rotterdam, ongoing, paid to the institution. Frank M.M.A. van der Heijden disclosed receiving funding from Janssen-Cilag, and Recordati. J. Jo Kim disclosed their institution received funding from the Patient-Centered Outcomes Research Institute and the National Institute of Mental Health. Marius Lahti-Pulkkinen received funding from the Academy of Finland. Dawn Misra disclosed receiving funding from the NIH. Kate E. Pickett disclosed that money was paid to her institution from UKRI and Wellcome Trust. Henning Tiemeier disclosed money was paid to their institution from the Dutch Research Medical Council. Heather J. Zar disclosed that money was paid to her institution from the Bill & Melinda Gates Foundation and the SA MRC. The other authors did not report any potential conflicts of interest., (Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
32. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials.
- Author
-
Jolliffe DA, Camargo CA Jr, Sluyter JD, Aglipay M, Aloia JF, Ganmaa D, Bergman P, Bischoff-Ferrari HA, Borzutzky A, Damsgaard CT, Dubnov-Raz G, Esposito S, Gilham C, Ginde AA, Golan-Tripto I, Goodall EC, Grant CC, Griffiths CJ, Hibbs AM, Janssens W, Khadilkar AV, Laaksi I, Lee MT, Loeb M, Maguire JL, Majak P, Mauger DT, Manaseki-Holland S, Murdoch DR, Nakashima A, Neale RE, Pham H, Rake C, Rees JR, Rosendahl J, Scragg R, Shah D, Shimizu Y, Simpson-Yap S, Trilok-Kumar G, Urashima M, and Martineau AR
- Subjects
- Dietary Supplements, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Respiratory Tract Infections diet therapy, Respiratory Tract Infections prevention & control, Vitamin D administration & dosage
- Abstract
Background: A 2017 meta-analysis of data from 25 randomised controlled trials (RCTs) of vitamin D supplementation for the prevention of acute respiratory infections (ARIs) revealed a protective effect of this intervention. We aimed to examine the link between vitamin D supplementation and prevention of ARIs in an updated meta-analysis., Methods: For this systematic review and meta-analysis, we searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and the ClinicalTrials.gov registry for studies listed from database inception to May 1, 2020. Double-blind RCTs of vitamin D
3 , vitamin D2 , or 25-hydroxyvitamin D (25[OH]D) supplementation for any duration, with a placebo or low-dose vitamin D control, were eligible if they had been approved by a research ethics committee, and if ARI incidence was collected prospectively and prespecified as an efficacy outcome. Studies reporting results of long-term follow-up of primary RCTs were excluded. Aggregated study-level data, stratified by baseline 25(OH)D concentration and age, were obtained from study authors. Using the proportion of participants in each trial who had one or more ARIs, we did a random-effects meta-analysis to obtain pooled odds ratios (ORs) and 95% CIs to estimate the effect of vitamin D supplementation on the risk of having one or more ARIs (primary outcome) compared with placebo. Subgroup analyses were done to estimate whether the effects of vitamin D supplementation on the risk of ARI varied according to baseline 25(OH)D concentration (<25 nmol/L vs 25·0-49·9 nmol/L vs 50·0-74·9 nmol/L vs >75·0 nmol/L), vitamin D dose (daily equivalent of <400 international units [IU] vs 400-1000 IU vs 1001-2000 IU vs >2000 IU), dosing frequency (daily vs weekly vs once per month to once every 3 months), trial duration (≤12 months vs >12 months), age at enrolment (<1·00 years vs 1·00-15·99 years vs 16·00-64·99 years vs ≥65·00 years), and presence versus absence of airway disease (ie, asthma only, COPD only, or unrestricted). Risk of bias was assessed with the Cochrane Collaboration Risk of Bias Tool. The study was registered with PROSPERO, CRD42020190633., Findings: We identified 1528 articles, of which 46 RCTs (75 541 participants) were eligible. Data for the primary outcome were obtained for 48 488 (98·1%) of 49 419 participants (aged 0-95 years) in 43 studies. A significantly lower proportion of participants in the vitamin D supplementation group had one or more ARIs (14 332 [61·3%] of 23 364 participants) than in the placebo group (14 217 [62·3%] of 22 802 participants), with an OR of 0·92 (95% CI 0·86-0·99; 37 studies; I2 =35·6%, pheterogeneity =0·018). No significant effect of vitamin D supplementation on the risk of having one or more ARIs was observed for any of the subgroups defined by baseline 25(OH)D concentration. However, protective effects of supplementation were observed in trials in which vitamin D was given in a daily dosing regimen (OR 0·78 [95% CI 0·65-0·94]; 19 studies; I2 =53·5%, pheterogeneity =0·003), at daily dose equivalents of 400-1000 IU (0·70 [0·55-0·89]; ten studies; I2 =31·2%, pheterogeneity =0·16), for a duration of 12 months or less (0·82 [0·72-0·93]; 29 studies; I2 =38·1%, pheterogeneity =0·021), and to participants aged 1·00-15·99 years at enrolment (0·71 [0·57-0·90]; 15 studies; I2 =46·0%, pheterogeneity =0·027). No significant interaction between allocation to the vitamin D supplementation group versus the placebo group and dose, dose frequency, study duration, or age was observed. In addition, no significant difference in the proportion of participants who had at least one serious adverse event in the vitamin supplementation group compared with the placebo group was observed (0·97 [0·86-1·07]; 36 studies; I2 =0·0%, pheterogeneity =0·99). Risk of bias within individual studies was assessed as being low for all but three trials., Interpretation: Despite evidence of significant heterogeneity across trials, vitamin D supplementation was safe and overall reduced the risk of ARI compared with placebo, although the risk reduction was small. Protection was associated with administration of daily doses of 400-1000 IU for up to 12 months, and age at enrolment of 1·00-15·99 years. The relevance of these findings to COVID-19 is not known and requires further investigation., Funding: None., Competing Interests: Declaration of interests ARM reports grants from the Fischer Family Trust, Pharma Nord, DSM Nutritional Products, the AIM Foundation, Cytoplan, and Thornton & Ross. CG reports grants from the Health Technology Assessment Programme of the UK National Institute of Health Research. WJ reports grants from Chiesi and Astra Zeneca. REN reports grants from the Australian National Health and Medical Research Council. ECG became an employee of GSK Canada in November 2013, after the completion and publication of her vitamin D RCT. AMH reports grants from NHLBI and the Office of Dietary Supplements. JRR reports grants from Dartmouth College, non-financial support (provision of study pills for trial) from Pfizer Consumer Healthcare and has a patent for calcium chemoprevention of adenoma (issued to John Baron & Dartmouth College). HAB-F reports grants from DSM Nutritional Products, travel expenses from Pfizer, and speaker honoraria from Wild Pharma, Mylan, and Roche Diagnostics. All other authors declare no competing interests. DAJ and ARM are the manuscript's guarantors and they affirm that this is an honest, accurate, and transparent account of the study being reported, and that no important aspects of the study have been omitted., (Copyright © 2021 Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
33. Asymptomatic Athlete With Short-Coupled Premature Ventricular Contractions.
- Author
-
Milman A, Belhassen B, Sabbag A, Dubnov-Raz G, and Beinart R
- Abstract
We present an asymptomatic 26-year-old athlete, with no family history of sudden cardiac death and no structural heart disease, who displayed short-coupled premature ventricular contractions on exercise test and Holter monitoring. The rarity of the case as well as management dilemmas are discussed. ( Level of Difficulty: Intermediate. )., Competing Interests: The authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
34. Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of aggregate data from randomised controlled trials.
- Author
-
Jolliffe DA, Camargo CA Jr, Sluyter JD, Aglipay M, Aloia JF, Ganmaa D, Bergman P, Borzutzky A, Damsgaard CT, Dubnov-Raz G, Esposito S, Gilham C, Ginde AA, Golan-Tripto I, Goodall EC, Grant CC, Griffiths CJ, Hibbs AM, Janssens W, Khadilkar AV, Laaksi I, Lee MT, Loeb M, Maguire JL, Majak P, Mauger DT, Manaseki-Holland S, Murdoch DR, Nakashima A, Neale RE, Pham H, Rake C, Rees JR, Rosendahl J, Scragg R, Shah D, Shimizu Y, Simpson-Yap S, Kumar GT, Urashima M, and Martineau AR
- Abstract
Background: A 2017 meta-analysis of data from 25 randomised controlled trials of vitamin D supplementation for the prevention of acute respiratory infections revealed a protective effect of the intervention. Since then, 20 new RCTs have been completed., Methods: Systematic review and meta-analysis of data from randomised controlled trials (RCTs) of vitamin D for ARI prevention using a random effects model. Pre-specified sub-group analyses were done to determine whether effects of vitamin D on risk of ARI varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration or dosing regimen. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and the ClinicalTrials.gov registry from inception to 1st May 2020. Double-blind RCTs of supplementation with vitamin D or calcidiol, of any duration, were eligible if they were approved by a Research Ethics Committee and if ARI incidence was collected prospectively and pre-specified as an efficacy outcome. Aggregate data, stratified by baseline 25(OH)D concentration, were obtained from study authors. The study was registered with PROSPERO (no. CRD42020190633)., Findings: We identified 45 eligible RCTs (total 73,384 participants). Data were obtained for 46,331 (98.0%) of 47,262 participants in 42 studies, aged 0 to 95 years. For the primary comparison of vitamin D supplementation vs. placebo, the intervention reduced risk of ARI overall (Odds Ratio [OR] 0.91, 95% CI 0.84 to 0.99; P for heterogeneity 0.01). No statistically significant effect of vitamin D was seen for any of the sub-groups defined by baseline 25(OH)D concentration. However, protective effects were seen for trials in which vitamin D was given using a daily dosing regimen (OR 0.75, 95% CI 0.61 to 0.93); at daily dose equivalents of 400-1000 IU (OR 0.70, 95% CI 0.55 to 0.89); and for a duration of ≤12 months (OR 0.82, 95% CI 0.72 to 0.93). No significant interaction was seen between allocation to vitamin D vs. placebo and dose frequency, dose size, or study duration. Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (OR 0.97, 95% CI 0.86 to 1.09). Risk of bias within individual studies was assessed as being low for all but three trials. A funnel plot showed left-sided asymmetry (P=0.008, Egger's test)., Interpretation: Vitamin D supplementation was safe and reduced risk of ARI, despite evidence of significant heterogeneity across trials. Protection was associated with administration of daily doses of 400-1000 IU vitamin D for up to 12 months. The relevance of these findings to COVID-19 is not known and requires investigation., Funding: None.
- Published
- 2020
- Full Text
- View/download PDF
35. Utilization of the medical clinic in an international acrobatic gymnastics championship.
- Author
-
Labkovski M, Maric D, Shostak A, and Dubnov-Raz G
- Published
- 2020
- Full Text
- View/download PDF
36. Ergogenic Effects of 8 Days of Sceletium Tortuosum Supplementation on Mood, Visual Tracking, and Reaction in Recreationally Trained Men and Women.
- Author
-
Hoffman JR, Markus I, Dubnov-Raz G, and Gepner Y
- Subjects
- Adult, Double-Blind Method, Female, Humans, Male, Performance-Enhancing Substances pharmacology, Young Adult, Affect drug effects, Eye Movements drug effects, Medicine, African Traditional methods, Plant Extracts pharmacology, Plants, Medicinal, Reaction Time drug effects
- Abstract
Hoffman, JR, Marcus, I, Dubnov-Raz, G, and Gepner, Y. Ergogenic effects of 8 days of Sceletium tortuosum supplementation on mood, visual tracking, and reaction in recreationally trained men and women. J Strength Cond Res 34(9): 2476-2481, 2020-Sceletium tortuosum (ST) is a South African plant that has been reported to promote a sense of well-being in healthy individuals and used in treating people with anxiety, stress, or depression. These studies have been conducted in middle-aged and older adults, but no investigations have been performed in a healthy, young adult population. Thus, the purpose of this study was to examine the effect of 8 days of ST extract (25-mg) supplementation on changes in reactive agility, visual tracking, and mood. Sixty recreationally trained men (n = 48) and women (n = 12), between 20 and 35 years, were randomly assigned to 1 of 2 groups: ST or placebo (PL). Subjects were tested on 2 occasions: before supplementation and 2-hours after supplementation on day 8. Subjects completed a subjective questionnaire to assess alertness and energy using a visual analog scale (VAS). In addition, subjects completed the Profile of Mood States questionnaire and performed reactive agility and visual tracking assessments. Significant improvements were noted for ST in complex reactive performance that required subjects to respond to repeated visual stimuli with a cognitive load compared with PL. However, no significant changes were noted between the groups in either VAS or total mood score. In addition, no differences were observed in simple reaction assessments. The results of this study demonstrate an ergogenic benefit in complex reactive tasks that include a cognitive load. However, in this subject population studied, no benefits in mood were observed.
- Published
- 2020
- Full Text
- View/download PDF
37. High prevalence of attention-deficit/hyperactivity disorder in adolescents with severe obesity seeking bariatric surgery.
- Author
-
Leib S, Gilon Mann T, Stein D, Vusiker I, Tokatly Latzer I, Ben-Ami M, Feigin A, and Dubnov-Raz G
- Subjects
- Adolescent, Adult, Female, Humans, Israel epidemiology, Male, Prevalence, Quality of Life, Surveys and Questionnaires, Young Adult, Attention Deficit Disorder with Hyperactivity epidemiology, Bariatric Surgery, Obesity, Morbid epidemiology, Obesity, Morbid surgery
- Abstract
Aim: To examine the prevalence of attention-deficit/hyperactivity disorder (ADHD) and related post-surgical weight loss in adolescents with severe obesity seeking bariatric surgery., Methods: The study population included 84 adolescents (age 13-19 years; 44 males, 40 females) with severe obesity who sought bariatric surgery at the Sheba Medical Centre in Israel during the years 2011-2017. Anthropometric and clinical data were collected from medical records. A subgroup of 20 participants filled questionnaires that evaluated ADHD-like symptoms, eating behaviours and quality of life. Data on adolescents that ultimately underwent surgery (n = 45) were also obtained., Results: The prevalence of ADHD was 28.6% in adolescents seeking bariatric surgery, much higher than that of the general adolescent population of Israel (17.1%, P < .001). There were no significant differences in reductions of weight, body mass index, body mass index standard deviation scores and body fat percent between participants with or without ADHD. In the subgroup that filled questionnaires, higher scores on ADHD-Rating Scale at baseline were associated with greater excess weight loss., Conclusion: The prevalence of ADHD in adolescents seeking bariatric surgery was very high. Diagnosed ADHD was not related to post-surgical weight loss, whereas baseline ADHD-related behaviour was associated with higher post-surgical weight loss., (© 2019 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
38. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.
- Author
-
Venkatesan S, Myles PR, Bolton KJ, Muthuri SG, Al Khuwaitir T, Anovadiya AP, Azziz-Baumgartner E, Bajjou T, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Chinbayar T, Cilloniz C, Denholm JT, Dominguez SR, Duarte PAD, Dubnov-Raz G, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Higuera Iglesias AL, Hoeger PH, Hu XY, Islam QT, Jiménez MF, Keijzers G, Khalili H, Kusznierz G, Kuzman I, Langenegger E, Lankarani KB, Leo YS, Libster RP, Linko R, Madanat F, Maltezos E, Mamun A, Manabe T, Metan G, Mickiene A, Mikić D, Mohn KGI, Oliva ME, Ozkan M, Parekh D, Paul M, Rath BA, Refaey S, Rodríguez AH, Sertogullarindan B, Skręt-Magierło J, Somer A, Talarek E, Tang JW, To K, Tran D, Uyeki TM, Vaudry W, Vidmar T, Zarogoulidis P, and Nguyen-Van-Tam JS
- Subjects
- Adolescent, Adrenal Cortex Hormones therapeutic use, Adult, Aged, Anti-Bacterial Agents therapeutic use, Child, Enzyme Inhibitors pharmacology, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult, Antiviral Agents therapeutic use, Enzyme Inhibitors therapeutic use, Influenza A Virus, H1N1 Subtype, Influenza, Human drug therapy, Influenza, Human epidemiology, Length of Stay, Neuraminidase antagonists & inhibitors, Pandemics
- Abstract
Background: The effect of neuraminidase inhibitor (NAI) treatment on length of stay (LoS) in patients hospitalized with influenza is unclear., Methods: We conducted a one-stage individual participant data (IPD) meta-analysis exploring the association between NAI treatment and LoS in patients hospitalized with 2009 influenza A(H1N1) virus (A[H1N1]pdm09) infection. Using mixed-effects negative binomial regression and adjusting for the propensity to receive NAI, antibiotic, and corticosteroid treatment, we calculated incidence rate ratios (IRRs) and 95% confidence intervals (CIs). Patients with a LoS of <1 day and those who died while hospitalized were excluded., Results: We analyzed data on 18 309 patients from 70 clinical centers. After adjustment, NAI treatment initiated at hospitalization was associated with a 19% reduction in the LoS among patients with clinically suspected or laboratory-confirmed influenza A(H1N1)pdm09 infection (IRR, 0.81; 95% CI, .78-.85), compared with later or no initiation of NAI treatment. Similar statistically significant associations were seen in all clinical subgroups. NAI treatment (at any time), compared with no NAI treatment, and NAI treatment initiated <2 days after symptom onset, compared with later or no initiation of NAI treatment, showed mixed patterns of association with the LoS., Conclusions: When patients hospitalized with influenza are treated with NAIs, treatment initiated on admission, regardless of time since symptom onset, is associated with a reduced LoS, compared with later or no initiation of treatment., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
39. [EXERCISE IS MEDICINE, INCLUDING STRENGTH TRAINING!]
- Author
-
Dubnov-Raz G
- Subjects
- Adolescent, Adult, Child, Exercise, Exercise Therapy, Female, Humans, Muscle Strength, Resistance Training, Sports
- Abstract
Introduction: This editorial focuses on strength training, an integral part of the exercise prescription for children, adolescents and adults. While filling the complete exercise prescription of aerobic and strength components provides maximal health benefits, it is noteworthy that even performing only aerobic activities or strength training is still better than no activity. The exercise prescription should be individually tailored to every person, according to her/his preferences, physical or technical limitations, medical conditions, etc. Some prefer, or are limited to, strength training only. Such activities improve muscle strength and athletic capabilities, in children mostly via improved neuromuscular control, and in youth and adults through muscle hypertrophy as well. From a health perspective, strength training had only been associated with better cardiovascular risk profiles in youth and with reduced mortality risks in adults. Interventional studies demonstrated that such training improves cardiovascular risk and physical functioning in youth and in adults, in healthy individuals and in those with chronic health conditions. Undoubtedly, strength training is medicine.
- Published
- 2019
40. Obsessive-compulsive symptomatology in female adolescent inpatients with restrictive compared with binge-purge eating disorders.
- Author
-
Lewis YD, Gilon Mann T, Enoch-Levy A, Dubnov-Raz G, Gothelf D, Weizman A, and Stein D
- Subjects
- Adolescent, Female, Humans, Inpatients statistics & numerical data, Feeding and Eating Disorders psychology, Inpatients psychology, Obsessive-Compulsive Disorder psychology
- Abstract
Objective: Strong relationships exist between obsessive-compulsive (OC) disorder and eating disorders (EDs). The aim of the study was to investigate whether OC symptoms would be expressed differently in different ED types., Method: Ninety-four female adolescent inpatients with restricting anorexia nervosa (AN-R), 67 with binge/purge AN (AN-B/P), and 48 with bulimia nervosa (BN) were assessed on admission and discharge using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), Yale-Brown-Cornell Eating Disorders Scale (YBC-EDS), Eating Attitude Test-26 (EAT-26), Beck Depression Inventory (BDI), and State-Trait Anxiety Inventory (STAI)., Results: On admission, patients with AN-B/P exhibited higher scores on the Y-BOCS, YBC-EDS, EAT-26, and BDI in comparison with patients with AN-R or BN. A significant improvement on all psychometric variables from admission to discharge was found for all participants taken together. Nonetheless, patients with AN-B/P and/or BN showed a greater improvement on Y-BOCS, BDI, and STAI than patients with AN-R, whereas no between-group difference was found for YBC-EDS and EAT-26., Conclusions: Obsessionality is more severe in acutely ill AN-B/P patients than in patients with AN-R and BN, whereas a greater improvement in obsessionality from the acutely ill to the stabilized ED condition is found in patients with binge/purge in comparison with restrictive pathology., (© 2018 John Wiley & Sons, Ltd and Eating Disorders Association.)
- Published
- 2019
- Full Text
- View/download PDF
41. Preferred weight-related terminology by parents of children with obesity.
- Author
-
Hirschfeld-Dicker L, Samuel RD, Tiram Vakrat E, and Dubnov-Raz G
- Subjects
- Adolescent, Adult, Aged, Child, Consumer Behavior, Female, Humans, Male, Middle Aged, Motivation, Young Adult, Attitude to Health, Body Weight, Parents psychology, Pediatric Obesity, Terminology as Topic
- Abstract
Aim: In order to improve weight-related discussion with patients and minimise their discomfort, the terminology used by medical staff should be carefully chosen. The aim of the study was to identify the most motivating weight-related terminology to use with children with obesity., Methods: Focus groups were used to generate a list of 12 weight-related terms in Hebrew, sent by a questionnaire to parents of children and adolescents with obesity. Terms were graded according to how desirable, stigmatising, blaming or motivating they were perceived. We identified the most positive and negative weight-based terms and conducted linear regressions to predict child motivation to lose weight when positive terms are used., Results: The least stigmatising and most motivating and desirable terms were 'unhealthy body weight' and 'unhealthy lifestyle'. Medical staff mostly used 'overweight', which was relatively inoffensive yet not very motivating. 'Fat/obese' ('Shamen') was the most stigmatising and blaming term and the least desired. Only 20% of parents endorsed a nonverbal graphical tool to describe body size., Conclusion: Our findings encourage using health-based terminology over weight-based terminology to promote treatment and lifestyle changes in children with obesity. Healthcare professionals should adopt patient-centred care and improve the weight-related terms they use with children with obesity., (©2018 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
42. Predicting Menstrual Recovery in Adolescents With Anorexia Nervosa Using Body Fat Percent Estimated by Bioimpedance Analysis.
- Author
-
Tokatly Latzer I, Kidron-Levy H, Stein D, Levy AE, Yosef G, Ziv-Baran T, and Dubnov-Raz G
- Subjects
- Adolescent, Adult, Amenorrhea etiology, Anorexia Nervosa rehabilitation, Anthropometry, Body Mass Index, Female, Hospitalization, Humans, Longitudinal Studies, Prospective Studies, Adipose Tissue metabolism, Amenorrhea physiopathology, Anorexia Nervosa complications, Anorexia Nervosa physiopathology, Electric Impedance, Menstruation physiology
- Abstract
Objective: To identify the threshold of total body fat percentage (TBF%) required for the resumption of menses (ROM) in hospitalized female adolescents with anorexia nervosa (AN) using bioimpedance analysis (BIA)., Methods: All female adolescents hospitalized with AN in our medical center were evaluated in a longitudinal prospective study during the years of 2012-2017. Anthropometric data, body fat measured by BIA, and hormonal determinants were collected periodically, in addition to routine medical and gynecological assessments., Results: Sixty-two participants presented with secondary amenorrhea, of which 20 remained with amenorrhea and 42 had ROM during hospitalization. At discharge, participants with ROM regained significantly more weight, and had higher mean body mass index (BMI), BMI standard deviation scores, and TBF% than those who remained with amenorrhea. Receiver operating characteristic analysis identified that a TBF% of 21.2% had the highest discriminative ability for ROM (sensitivity = 88%, specificity = 85%, positive predictive value = 93%). Compared with the anthropometric parameters, TBF% had the highest area under curve (AUC = .895), which significantly differed from that of BMI standard deviation scores (AUC = .643, p = .007) and body weight (AUC = .678, p = .03)., Conclusions: BIA is a safe and relatively simple method to assess the TBF% required for the return of balanced menstrual cycles in female adolescents with AN. The TBF% with the highest discriminative ability for menstrual resumption as assessed by BIA is 21.2%., (Copyright © 2018. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
43. Counter-Terror Fighting Task: Metabolic Demand and Energy Systems' Contributions.
- Author
-
Inbar O, Petluk L, and Dubnov-Raz G
- Subjects
- Adult, Athletes statistics & numerical data, Energy Metabolism physiology, Humans, Male, Oxygen Consumption physiology, Physiological Phenomena, Energy Intake physiology, Military Personnel statistics & numerical data, Police statistics & numerical data, Terrorism
- Abstract
Introduction: In light of the recent increase in terrorist events around the globe, it is surprising that the metabolic demand of counter-terror fighting tasks had not yet been published in the scientific literature. The purpose of this study, therefore, was to examine the metabolic demand and the contribution of the three energy systems to a typical simulated counter-terror combat scenario., Materials and Methods: Oxygen uptake and carbon dioxide output (VO2, VCO2), heart rate, ventilatory responses, and blood lactate concentration were measured in 12 randomly selected elite Special Forces police fighters (mean age 33.3 ± 3.6 years). The fighting task involved ascending flights of stairs, climbing a ladder, shooting on hiding terrorists, performing a search and rescue, relocating a wounded colleague, and then descending and exiting from a seven-floor building., Results: The fighting scenario lasted an average of 4:56 ± 0:22 min. Measured oxygen uptake averaged 31.1 ± 2.0 ml kg min-1 (57.7% of VO2max) with an average peak of 37.7 ± 8.1 ml kg min-1 (75.5% of VO2max). Average and peak heart rates were 160.4 ± 12.2 beats min-1 (85% of the HRmax) and 175.5 ± 10.5 beats min-1 (94% of HRmax), respectively. The energy cost of the fighting scenario averaged 74.3 ± 9.9 Kcal, with 75.5% of the energy generated by aerobic pathways, 14.1% from anaerobic lactacid (glycolytic) and 10.4% from anaerobic a-lactacid (phosphogenic) energy sources., Conclusions: This study provided novel information related to the physiological demands and the metabolic fuel supplies during a typical counter-terror-fighting task of elite Special Forces. Such information is instrumental in planning and conducting adequate training programs and nutrition support for counter-terror fighting units., (© Association of Military Surgeons of the United States 2018. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
44. High Familial Correlation in Methylphenidate Response and Side Effect Profile.
- Author
-
Gazer-Snitovsky M, Brand-Gothelf A, Dubnov-Raz G, Weizman A, and Gothelf D
- Subjects
- Adolescent, Adult, Appetite drug effects, Attention Deficit Disorder with Hyperactivity diagnosis, Attention Deficit Disorder with Hyperactivity psychology, Central Nervous System Stimulants adverse effects, Child, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Methylphenidate adverse effects, Parents, Siblings, Sleep Initiation and Maintenance Disorders chemically induced, Treatment Outcome, Attention Deficit Disorder with Hyperactivity drug therapy, Attention Deficit Disorder with Hyperactivity genetics, Central Nervous System Stimulants therapeutic use, Methylphenidate therapeutic use
- Abstract
Objective: To examine whether a familial tendency exists in clinical response to methylphenidate., Method: Nineteen pairs of siblings or parent-child stimulant-naive individuals with ADHD were prescribed methylphenidate-immediate release, and were comprehensively evaluated at baseline, Week 2, and Week 4, using the ADHD Rating Scale IV, Clinical Global Impression Scale, and the Barkley Side Effects Rating Scale., Results: We found significant intraclass correlations in family member response to methylphenidate-immediate release and side effect profile, including emotional symptoms and loss of appetite and weight., Conclusion: Family history of response to methylphenidate should be taken into account when treating ADHD.
- Published
- 2019
- Full Text
- View/download PDF
45. Vitamin D supplementation to prevent acute respiratory infections: individual participant data meta-analysis.
- Author
-
Martineau AR, Jolliffe DA, Greenberg L, Aloia JF, Bergman P, Dubnov-Raz G, Esposito S, Ganmaa D, Ginde AA, Goodall EC, Grant CC, Janssens W, Jensen ME, Kerley CP, Laaksi I, Manaseki-Holland S, Mauger D, Murdoch DR, Neale R, Rees JR, Simpson S, Stelmach I, Trilok Kumar G, Urashima M, Camargo CA, Griffiths CJ, and Hooper RL
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Body Mass Index, Child, Child, Preschool, Cholecalciferol administration & dosage, Comorbidity, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Ergocalciferols administration & dosage, Female, Humans, Infant, Influenza Vaccines administration & dosage, Male, Middle Aged, Randomized Controlled Trials as Topic, Vitamin D administration & dosage, Vitamin D Deficiency drug therapy, Young Adult, Dietary Supplements, Respiratory Tract Infections prevention & control, Vitamin D therapeutic use
- Abstract
Background: Randomised controlled trials (RCTs) exploring the potential of vitamin D to prevent acute respiratory infections have yielded mixed results. Individual participant data (IPD) meta-analysis has the potential to identify factors that may explain this heterogeneity., Objectives: To assess the overall effect of vitamin D supplementation on the risk of acute respiratory infections (ARIs) and to identify factors modifying this effect., Data Sources: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, ClinicalTrials.gov and the International Standard Randomised Controlled Trials Number (ISRCTN) registry., Study Selection: Randomised, double-blind, placebo-controlled trials of supplementation with vitamin D
3 or vitamin D2 of any duration having incidence of acute respiratory infection as a prespecified efficacy outcome were selected., Study Appraisal: Study quality was assessed using the Cochrane Collaboration Risk of Bias tool to assess sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, completeness of outcome data, evidence of selective outcome reporting and other potential threats to validity., Results: We identified 25 eligible RCTs (a total of 11,321 participants, aged from 0 to 95 years). IPD were obtained for 10,933 out of 11,321 (96.6%) participants. Vitamin D supplementation reduced the risk of ARI among all participants [adjusted odds ratio (aOR) 0.88, 95% confidence interval (CI) 0.81 to 0.96; heterogeneity p < 0.001]. Subgroup analysis revealed that protective effects were seen in individuals receiving daily or weekly vitamin D without additional bolus doses (aOR 0.81, 95% CI 0.72 to 0.91), but not in those receiving one or more bolus doses (aOR 0.97, 95% CI 0.86 to 1.10; p = 0.05). Among those receiving daily or weekly vitamin D, protective effects of vitamin D were stronger in individuals with a baseline 25-hydroxyvitamin D [25(OH)D] concentration of < 25 nmol/l (aOR 0.30, 95% CI 0.17 to 0.53) than in those with a baseline 25(OH)D concentration of ≥ 25 nmol/l (aOR 0.75, 95% CI 0.60 to 0.95; p = 0.006). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (aOR 0.98, 95% CI 0.80 to 1.20; p = 0.83). The body of evidence contributing to these analyses was assessed as being of high quality., Limitations: Our study had limited power to detect the effects of vitamin D supplementation on the risk of upper versus lower respiratory infection, analysed separately., Conclusions: Vitamin D supplementation was safe, and it protected against ARIs overall. Very deficient individuals and those not receiving bolus doses experienced the benefit. Incorporation of additional IPD from ongoing trials in the field has the potential to increase statistical power for analyses of secondary outcomes., Study Registration: This study is registered as PROSPERO CRD42014013953., Funding: The National Institute for Health Research Health Technology Assessment programme., Competing Interests: Susanna Esposito reports grants and personal fees from GlaxoSmithKline (GSK) plc (GSK House, Middlesex, UK), grants and personal fees from Pfizer Inc. (New York, NY, USA), grants and personal fees from Sanofi Pasteur MSD [Sanofi Pasteur (Lyon France) and Merck Sharp & Dohme Corp. (MSD, Kenilworth, NJ, USA)], grants from DuPage Medical Group (DMG, Downers Grove, IL, USA), personal fees from Valeas S.p.A. (Milan, Italy), and grants and personal fees from Vifor Pharma (Bern, Switzerland), outside the submitted work. Emma Goodall reports personal fees from GSK outside the submitted work. Wim Janssens reports grants from Instituut voor Innovatie door Wetenschap en Technologie (IWT)–Vlaanderen and from Laboratoires SMB (Brussels, Belgium) during the conduct of the study. David Mauger reports funding from the National Heart, Lung, and Blood Institute, MA, USA. Rachel Neale reports grants from the National Institutes of Health and the Medical Research Council during the conduct of the study. Judy R Rees reports that a use patent is held by Dartmouth College and Dr John A Baron for calcium as a chemopreventive agent. Dr Baron is not an author on this paper but is the principal investigator of the parent study from which the study by Rees (Rees JR, Hendricks K, Barry EL, Peacock JL, Mott LA, Sandler RS, et al. Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial. Clin Infect Dis 2013;57:1384–92) was conducted. The patent was previously licensed by Pfizer (with royalties), but has not been licensed for about 5 years. Judy R Rees is not involved in the patent and the patent does not involve vitamin D.- Published
- 2019
- Full Text
- View/download PDF
46. [PRINCIPLES FOR THE INTERPRETATION OF CARDIOPULMONARY EXERCISE TESTS (CPET)].
- Author
-
Inbar O, Katz U, Dubnov-Raz G, and Epstein Y
- Subjects
- Humans, Prognosis, Cardiovascular Diseases diagnosis, Exercise Test, Exercise Tolerance
- Abstract
Introduction: The cardiopulmonary exercise test (CPET) permits the most accurate and reproducible quantification of cardiopulmonary fitness, a grading of the etiology and severity of cardiopulmonary impairments, and an objective assessment of the response to an intervention. Moreover, over the last three decades, a large volume of research has been directed toward the utility of CPET as a diagnostic and prognostic tool; these studies have established CPET as a scientifically sound and, therefore, clinically valuable method for accurately assessing exercise limitation and prognosis in various disease states. The CPET is relatively easy to perform, yet complex in the interpretation of the results. The current review presents the principles of the analytic process of the test results, in order to obtain possible diagnoses.
- Published
- 2018
47. Recovery of upper-body muscle power after short intensive exercise: comparing boys and men.
- Author
-
Weinstein Y, Inbar O, Mor-Unikovski R, Luder A, and Dubnov-Raz G
- Subjects
- Adult, Age Factors, Biomarkers blood, Child, Exercise Test methods, Heart Rate, Humans, Lactic Acid blood, Male, Sex Factors, Time Factors, Upper Extremity, Exercise, Muscle Contraction, Muscle Strength, Muscle, Skeletal physiology
- Abstract
Purpose: Boys' lower-body muscle power generation (PO) recovers faster than men's following intensive exercise. The purpose of this study was to examine whether boys differ from adult men in recovering from upper-body muscle power generation following intensive exercise., Methods: Fifteen prepubertal boys (M ± SD age 10.6 ± 1.0 years) and 13 men (31.1 ± 5.0 years) performed two upper-body Wingate Anaerobic Tests (WAnT), separated by either 2-min or 10-min recovery intervals. WAnT parameters, pre-and post-WAnT heart rates (HR), and blood lactate ([La]) were measured during recovery from the WAnTs., Results: Boys' mean power (MP) of the repeated WAnT (WAnT
2 ) following 2- and 10-min recoveries was 97.3 ± 7.2% and 99.4 ± 3.9%, respectively, compared to MP of the first test (WAnT1 ) (p > 0.05 for both tests). In contrast, in men's MP of the WAnT2 following the 2-min recovery, was significantly lower than that of the WAnT1 (84.4 ± 6.7%, p = 0.0001). While boys' and men's HR recovery after 2 min differed significantly (p = 0.046), no between-group differences were found following the 10-min recovery. Peak [La] in boys was 37-44% lower than that in men (p = 0.002)., Conclusions: The faster recovery of PO in boys after supra-maximal upper-body exercise is partially explained by the lower power generated by boys, attributed in part to a lower anaerobic capacity and to the greater relative contribution of aerobic processes to performance and recovery from anaerobic-type tasks. Further research is needed to determine the physiologic, neurologic and biochemical basis of the rapid muscle power recovery in children.- Published
- 2018
- Full Text
- View/download PDF
48. Different attention bias patterns in anorexia nervosa restricting and binge/purge types.
- Author
-
Gilon Mann T, Hamdan S, Bar-Haim Y, Lazarov A, Enoch-Levy A, Dubnov-Raz G, Treasure J, and Stein D
- Subjects
- Adolescent, Anorexia Nervosa diagnosis, Binge-Eating Disorder diagnosis, Female, Humans, Male, Social Perception, Surveys and Questionnaires, Young Adult, Anorexia Nervosa psychology, Anxiety, Anxiety Disorders psychology, Attentional Bias, Binge-Eating Disorder psychology, Depression psychology
- Abstract
Patients with anorexia nervosa (AN) have been shown to display both elevated anxiety and attentional biases in threat processing. In this study, we compared threat-related attention patterns of patients with AN restricting type (AN-R; n = 32), AN binge/purge type (AN-B/P; n = 23), and healthy controls (n = 19). A dot-probe task with either eating disorder-related or general and social anxiety-related words was used to measure attention patterns. Severity of eating disorder symptoms, depression, anxiety, and stress were also assessed. Patients with AN-R showed vigilance to both types of threat words, whereas patients with AN-B/P showed avoidance of both threat types. Healthy control participants did not show any attention bias. Attention bias was not associated with any of the demographic, clinical, and psychometric parameters introduced. These findings suggest that there are differential patterns of attention allocation in patients with AN-R and AN-B/P. More research is needed to identify what causes/underlies these differential patterns., (Copyright © 2018 John Wiley & Sons, Ltd and Eating Disorders Association.)
- Published
- 2018
- Full Text
- View/download PDF
49. Mutations in PPCS, Encoding Phosphopantothenoylcysteine Synthetase, Cause Autosomal-Recessive Dilated Cardiomyopathy.
- Author
-
Iuso A, Wiersma M, Schüller HJ, Pode-Shakked B, Marek-Yagel D, Grigat M, Schwarzmayr T, Berutti R, Alhaddad B, Kanon B, Grzeschik NA, Okun JG, Perles Z, Salem Y, Barel O, Vardi A, Rubinshtein M, Tirosh T, Dubnov-Raz G, Messias AC, Terrile C, Barshack I, Volkov A, Avivi C, Eyal E, Mastantuono E, Kumbar M, Abudi S, Braunisch M, Strom TM, Meitinger T, Hoffmann GF, Prokisch H, Haack TB, Brundel BJJM, Haas D, Sibon OCM, and Anikster Y
- Subjects
- Amino Acid Sequence, Animals, Biosynthetic Pathways, Cardiomyopathy, Dilated diagnosis, Carnitine analogs & derivatives, Carnitine metabolism, Child, Preschool, Coenzyme A biosynthesis, Demography, Drosophila, Enzyme Stability, Female, Fibroblasts metabolism, Heart physiopathology, High-Throughput Nucleotide Sequencing, Homozygote, Humans, Infant, Infant, Newborn, Magnetic Resonance Imaging, Male, Pantetheine administration & dosage, Pantetheine analogs & derivatives, Pedigree, Peptide Synthases blood, Peptide Synthases chemistry, Peptide Synthases deficiency, Reproducibility of Results, Saccharomyces cerevisiae genetics, Cardiomyopathy, Dilated enzymology, Cardiomyopathy, Dilated genetics, Genes, Recessive, Mutation genetics, Peptide Synthases genetics
- Abstract
Coenzyme A (CoA) is an essential metabolic cofactor used by around 4% of cellular enzymes. Its role is to carry and transfer acetyl and acyl groups to other molecules. Cells can synthesize CoA de novo from vitamin B5 (pantothenate) through five consecutive enzymatic steps. Phosphopantothenoylcysteine synthetase (PPCS) catalyzes the second step of the pathway during which phosphopantothenate reacts with ATP and cysteine to form phosphopantothenoylcysteine. Inborn errors of CoA biosynthesis have been implicated in neurodegeneration with brain iron accumulation (NBIA), a group of rare neurological disorders characterized by accumulation of iron in the basal ganglia and progressive neurodegeneration. Exome sequencing in five individuals from two unrelated families presenting with dilated cardiomyopathy revealed biallelic mutations in PPCS, linking CoA synthesis with a cardiac phenotype. Studies in yeast and fruit flies confirmed the pathogenicity of identified mutations. Biochemical analysis revealed a decrease in CoA levels in fibroblasts of all affected individuals. CoA biosynthesis can occur with pantethine as a source independent from PPCS, suggesting pantethine as targeted treatment for the affected individuals still alive., (Copyright © 2018 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
50. [MEDICAL ASPECTS IN THE DIAGNOSIS AND TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER].
- Author
-
Amsalem D, Dar N, Efron M, Ashkenasi A, Yaari E, Dubnov-Raz G, Levy-Shraga Y, Kushnir Y, and Gothelf D
- Subjects
- Humans, Attention Deficit Disorder with Hyperactivity diagnosis, Attention Deficit Disorder with Hyperactivity therapy
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.